Recruiting

Circulating Tumor Cells

Sponsor:

Oscar Goodman, Jr.

Code:

NCT02123862

Conditions

Prostate Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to evaluate the number of circulating tumor cells (CTC) before and after treatment using an experimental method for detecting CTC, compared to commercial CTC assay results, in patients with prostate, breast or colorectal cancers.

Experiments will be done to develop a new assay technique and also test how CTC react to commonly used drugs. This information will be analyzed to determine if the experimental assays can be helpful in the future to predict how a patient's cancer may react to certain treatments.

The research experiments will also attempt to grow CTC for long-term or "immortal" cell lines that can be further studied for proteins and gene mutations related to the specific tumor (not familial), and testing for sensitivity to drugs.

Blood samples will be collected at specific time points during routine medical care from patients with prostate, breast, colorectal or other solid tumor cancer. Samples will also be collected from patients with no cancer for comparison purposes. Samples for the experimental tests will be identified only by codes and results will not be shared with participants. Patients with prostate, breast or colorectal cancer will also have blood samples drawn for commercial CTC assays as part of their standard care.

Conditions

Prostate Cancer

Study ID

NCT02123862

Start date

Apr, 2014

Status verified date

Jan, 2015

Completion date

Apr, 2018

Anticipated

Primary completion date

Apr, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Diagnosis of prostate cancer, breast cancer, or other cancer, OR have no cancer. All participants will be having blood drawn at Comprehensive Cancer Centers of Nevada as part of their routine care.
  • 18 years of age or older.
  • All participants must be informed of the investigational nature of this study, and must sign and give written informed consent in accordance with institutional and FDA guidelines.

Exclusion Criteria:

-

Study Design

Enrollment

220 participants

Anticipated

Interventions and Outcome Measures

Arms

Prostate Cancer

Breast Cancer

Colorectal Cancer

Solid Tumor

Benign Condition

Primary outcome measure

  • Evaluate novel CTC assay method as a predictive tool for prostate, breast and colorectal cancers. [ Time Frame: Completed within 12 months after last sample collected. ]

Central Contacts and Locations

Central contacts

Oscar B Goodman, Jr., MD, PhD

702-952-1251oscar.goodman@usoncology.com

Joyon D Pekkattil

702-952-3714joyson.pekkattil@usoncology.com

Locations

Comprehensive Cancer Centers of Nevada

Recruiting

Las Vegas, Nevada, United States, 89148

Contacts

Oscar B Goodman, Jr., MD, PhD

702-952-1251oscar.goodman@usoncology.com

Joyson D Pekkattil

702-952-3714joyson.pekkattil@usoncology.com

More Information

Sponsor

Oscar Goodman, Jr.

Last update posted

Jan 19, 2015

Last verified

Jan, 2015

Keywords

  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Colon Cancer
  • Rectal Cancer
  • Cancer
  • Solid Tumor
  • Metastatic
  • Circulating Tumor Cells

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Oscar Goodman, Jr. on 2015-01-19.